Fulgent Genetics (FLGT) EBITDA (2015 - 2026)

Fulgent Genetics has reported EBITDA for 12 years, with the latest figure at -$36.1 million in Q2 2026.

• Quarterly EBITDA fell 82.99% year-over-year to -$36.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$86.5 million (down 19.01% YoY) and the FY2025 annual result came in at -$91.1 million, down 23.24% from the prior year.
• EBITDA declined to -$36.1 million in Q2 2026 per FLGT's latest filing, from -$34.6 million in the prior quarter.
• Over five years, EBITDA peaked at $201.9 million in Q1 2022 and troughed at -$151.1 million in Q4 2023.
• A 5-year average of -$9.1 million and a median of -$18.0 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2024 and 2025: EBITDA sank 8080.84% in 2024, then soared 96.9% in 2025.
• Over 5 years, EBITDA stood at $17.0 million in 2022, then plunged by 988.95% to -$151.1 million in 2023, then surged by 89.32% to -$16.1 million in 2024, then jumped by 96.9% to -$500000.0 in 2025, then sank by 7114.6% to -$36.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$36.1 million, -$34.6 million, and -$500000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.